A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

February 29, 2012

Conditions
Advanced Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Fulvestrant

250 intramuscular injection

DRUG

Fulvestrant

500 mg intramuscular injection

Trial Locations (35)

Unknown

Research Site, Nagoya

Research Site, Asahi

Research Site, Chiba

Research Site, Matsuyama

Research Site, Fukuoka

Research Site, Kitakyushu

Research Site, Kurume

Research Site, Daito

Research Site, Kōriyama

Research Site, Ōta

Research Site, Fukuyama

Research Site, Hiroshima

Research Site, Kure

Research Site, Sapporo

Research Site, Amagasaki

Research Site, Matsubaracho

Research Site, Isehara

Research Site, Sagamihara

Research Site, Yokohama

Research Site, Kumamoto

Research Site, Sendai

Research Site, Niigata

Research Site, Ōita

Research Site, Kurashiki

Research Site, Izumisano

Research Site, Osaka

Research Site, Sakai

Research Site, Suita

Research Site, Morohongō

Research Site, Shinden

Research Site, Shizuoka

Research Site, Shimotsuke

Research Site, Chūō

Research Site, Koto-ku

Research Site, Kawasaki

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY